

Triptodur (triptorelin)
 Effective 12/1/2019

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Triptorelin is an agonist analog of gonadotropin releasing hormone (GnRH) and causes suppression of ovarian and testicular steroidogenesis due to decreased levels of LH and FSH with subsequent decrease in testosterone (male) and estrogen (female) levels. Triptodur is FDA indicated for treatment of central precocious puberty (CPP) in patients 2 years and older

Coverage Guidelines

Authorization may be granted for members who are currently receiving treatment with Triptodur excluding when the product is obtained as samples or via manufacturer's patient assistance programs

OR

Authorization may be when the following criteria are met, and documentation has been submitted:

1. The member has a diagnosis of CPP with onset of secondary sex characteristics before age eight for females or age nine for males.
2. Member is at least 2 years of age
3. The prescriber is a pediatric endocrinologist or documentation of a consultation with a pediatric endocrinologist is provided
4. The member has had an inadequate response, adverse reaction or a contraindication to Lupron.

Limitations

1. Approvals will be granted for females up to the age of 12 and up to the age of 13 for males

References

1. Triptodur (triptorelin) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; January 2019.
2. Clinical practice. Precocious puberty PubMed; N Engl J Med. 2008;358(22):2366.

3. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty; *J Clin Endocrinol Metab.* 2005;90(3):1371. Epub 2004 Dec 14. [PubMed]
4. Leschek EW, Flor AC, Bryant JC, et al. Effect of Antiandrogen, Aromatase Inhibitor, and Gonadotropin-releasing Hormone Analog on Adult Height in Familial Male Precocious Puberty. *J Pediatr* 2017; 190:229
5. Klein K, Yang J, Aisenberg J, et al. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. *J Pediatr Endocrinol Metab* 2016; 29:1241
6. Lupron Depot-PED (leuprolide) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2020.
7. Bangalore Krishna K, Fuqua JS, Rogol AD, et al. Use of Gonadotropin-Releasing Hormone Analogs in Children: Update by an International Consortium. *Horm Res Paediatr* 2019; 91:357
8. Demirbilek H, Alikasifoglu A, Gonc NE, et al. Assessment of gonadotrophin suppression in girls treated with GnRH analogue for central precocious puberty; validity of single luteinizing hormone measurement after leuprolide acetate injection. *Clin Endocrinol (Oxf)* 2012; 76:1

Review History

09/24/18 – Reviewed

01/01/19 – Implemented

09/18/19 – Removed testing requirements, added started & stabilized requirement, and combined male and female criteria

09/16/20 – Reviewed at P&T.

